{"title":"小鼠肿瘤坏死因子的药动学。","authors":"D A Flick, G E Gifford","doi":"10.3109/08923978609031087","DOIUrl":null,"url":null,"abstract":"<p><p>The in vivo administration of tumor necrosis factor (TNF) provides a new approach to the immunotherapeutic treatment of tumors. We evaluated the pharmacokinetics of murine tumor necrosis factor in mice as a model for application in the human system. TNF had a clearance of 0.013 ml/min/g and a serum half life of 10.5 minutes. Its volume of distribution was consistent with the extracellular space. This information can provide parameters by which to select optimal modes of treatment for eradication of in vivo neoplasms.</p>","PeriodicalId":16049,"journal":{"name":"Journal of immunopharmacology","volume":"8 1","pages":"89-97"},"PeriodicalIF":0.0000,"publicationDate":"1986-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/08923978609031087","citationCount":"55","resultStr":"{\"title\":\"Pharmacokinetics of murine tumor necrosis factor.\",\"authors\":\"D A Flick, G E Gifford\",\"doi\":\"10.3109/08923978609031087\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The in vivo administration of tumor necrosis factor (TNF) provides a new approach to the immunotherapeutic treatment of tumors. We evaluated the pharmacokinetics of murine tumor necrosis factor in mice as a model for application in the human system. TNF had a clearance of 0.013 ml/min/g and a serum half life of 10.5 minutes. Its volume of distribution was consistent with the extracellular space. This information can provide parameters by which to select optimal modes of treatment for eradication of in vivo neoplasms.</p>\",\"PeriodicalId\":16049,\"journal\":{\"name\":\"Journal of immunopharmacology\",\"volume\":\"8 1\",\"pages\":\"89-97\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1986-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.3109/08923978609031087\",\"citationCount\":\"55\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of immunopharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3109/08923978609031087\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of immunopharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3109/08923978609031087","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The in vivo administration of tumor necrosis factor (TNF) provides a new approach to the immunotherapeutic treatment of tumors. We evaluated the pharmacokinetics of murine tumor necrosis factor in mice as a model for application in the human system. TNF had a clearance of 0.013 ml/min/g and a serum half life of 10.5 minutes. Its volume of distribution was consistent with the extracellular space. This information can provide parameters by which to select optimal modes of treatment for eradication of in vivo neoplasms.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
